Effect of omalizumab on adenosine 5′-monophosphate responsiveness in subjects with allergic asthma

International Archives of Allergy and Immunology

Volumn 139, Issue 2, 2006, Pages 122-131

  Prieto, L ^a   Gutierrez V ^a   Colas C ^b   Tabar, A ^c   Perez Frances C ^a   Bruno, L ^a   Uixera, S ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c Universidad Pública de Navarra   (Spain)

Author keywords

Adenosine 5 monophosphate; Allergic asthma; Anti immunoglobulin E; Immunoglobulin E; Methacholine; Omalizumab

Indexed keywords

ADENOSINE PHOSPHATE; IMMUNOGLOBULIN E; METHACHOLINE; OMALIZUMAB; PLACEBO;

ADULT; AIRWAY; ALLERGIC ASTHMA; ARTICLE; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

ADENOSINE MONOPHOSPHATE; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; BRONCHOCONSTRICTOR AGENTS; FEMALE; HUMANS; LUNG; MALE; METHACHOLINE CHLORIDE; MIDDLE AGED; RESPIRATORY HYPERSENSITIVITY;

EID: 31744446879     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090387     Document Type: Article

References (42)

1. Polosa R, Ng WH, Crimi N, Vancheri C, Holgate ST, Church MK, Mistretta D: Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am J Respir Crit Care Med 1995;151:624-629.
2. Forsyte P, McGarvey LPA, Heaney LG, McMahon J, Ennis M: Adenosine induces histamine release from human bronchoalveolar lavage mast cells. Clin Sci 1999;96:349-355.
3. Polosa R, Lau LCK, Holgate ST: Inhibition of adenosine 5′-monophosphate- and methacho-line-induced bronchoconstriction in asthma by inhaled frusemide. Eur Respir J 1990;3:665-672.
4. Prieto L, Gutiérrez V, Cervera A, Liñana J: Airway obstruction induced by inhaled acetal-dehyde in asthma: repeatability and relationship to adenosine 5′-monophosphate responsiveness. J Invest Allergol Clin Immunol 2002; 12:91-98.
5. Prieto L, Gutiérrez V, Liñana J, Marín J: Bronchoconstriction induced by inhaled adenosine 5′-monophosphate in subjects with allergic rhinitis. Eur Respir J 2001;17:64-70.
6. Prieto L, Gutiérrez V, Marín J: Relationship between airway sensitivity to adenosine 5′-monophosphate and the shape of the concentration-response curve to methacholine in subjects with allergic rhinitis. Respir Med 2001; 95:457-463.
7. Prieto L, Gutiérrez V, Uixera S: Exhaled nitric oxide and bronchial responsiveness to adenosine 5′-monophosphate in subjects with allergic rhinitis. Chest 2002;121:1853-1859.
8. Pauwels R, Joos G, van der Straeten M: Bronchial hyperresponsiveness is not bronchial hyperresponsiveness is not bronchial asthma. Clin Allergy 1988;18:317-321.
9. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271-277.
10. Court CS, Cook DG, Strachan DP: Comparative epidemiology of atopic and non-atopic wheeze and diagnosed asthma in a national sample of English adults. Thorax 2002;57: 951-957.
11. Holt PG, Macaubas C, Stumbles PA, Sly PD: The role of allergy in the development of asthma. Nature 1999;402(suppl):B12-B17.
12. Williams CM, Gallis SJ: The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol 2000;105:847-859.
13. Milgrom H, Fick RB, Su JQK, et al: Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341:1966-1973.
14. Busse W, Corren J, Lanier BQ, et al: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
15. Soler M, Matz J, Townley R, et al: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-261.
16. Buhl R, Soler M, Matz J, et al: Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:73-78.
17. Milgrom H, Berger W, Nayak A, et al: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36.
18. Holgate ST, Chuchalin AG, Hébert J, et al: Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34: 632-638.
19. Humbert M, Beasley R, Ayres J, et al: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-316.
20. Vignola AM, Humbert M, Bousquet J, et al: Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-717.
21. Presta L, Shields R, O'Connell L, et al: The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994; 269:26368-26373.
22. MacGlashan DWJ, Bochner BS, Adelman DC, et al: Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-1445.
23. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S: Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 2004;114: 527-530.
24. Prussin G, Griffith DT, Boesel KM, Liu H, Foster B, Casale TB: Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol 2003;112:1147-1154.
25. Fahy JV, Fleming E, Wong HH, et al: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-1834.
26. Boulet LP, Chapman KR, Côté J, et al: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-1840.
27. Djukanovic R, Wilson SJ, Kraft M, et al: Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-593.
28. Malveaux FJ, Couroy MC, Adkinson NF, Lichtenstein LM: IgE receptors on human basophils: relationship to serum IgE concentration. J Clin Invest 1978;62:176-181.
29. American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-244.
30. American Thoracic Society: Standardization of spirometry 1987 update. Am Rev Respir Dis 1987;136:1285-1294.
31. Quanjer PH: Standardized lung function testing. Bull Eur Physiopathol Respir 1983;19:1-95.
32. Chai H, Farr RS, Froehlich LA, et al: Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975;56:323-327.
33. American Thoracic Society: Guidelines for methacholine and exercise challenge testing - 1999. Am J Respir Crit Care Med 2000;161: 309-329.
34. Prieto L, Marin J: Methacholine inhalation challenges; practical consequences of using duplicate spirogram after each concentration. Ann Allergy 1993;70:487-490.
35. 20: comparison of linear and logarithmic interpolation. Chest 1983;84:505-506.
36. Lin H, Boesel KM, Griffith DT, et al: Omalizumab rapidly decrease nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 2004;113:297-302.
37. O'Connor BJ, Ridge SM, Barnes PJ, Fuller RW: Greater effect of inhaled budesonide on adenosine 5′-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma. Am Rev Respir Dis 1992; 146:560-564.
38. Taylor DA, Jensen MW, Kanabar V, et al: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999;160:237-243.
39. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O'Connor BJ: Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma. J Allergy Clin Immunol 2002; 110:603-606.
40. Noga O, Hanf G, Kunkel G: Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003;131:46-52.
41. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD: Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991;325: 1067-1071.
42. Moreno RH, Hogg JC, Pare PD: Mechanics of airway narrowing. Am Rev Respir Dis 1986; 133:1171-1180.